Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.69 |
| ▸ | HTR1A | P08908 | 2/20 | 0.61 |
| ▸ | MPO | P05164 | 9/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31535627 | 1.00 | HTR2A (0.71) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL5636918 | 0.90 | HTR2A (0.67) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL517983 | 0.86 | MPO (0.73) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL29571866 | 0.86 | MPO (0.73) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL7710633 | 0.83 | HTR2A (0.71) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL743153 | 0.83 | HTR2A (1.00) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL28368250 | 0.83 | HTR2A (1.00) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL6846106 | 0.83 | HTR2A (0.71) | HTR2AGPR84HTR1AMPOTRPM8 | |
| SCHEMBL30952647 | 0.83 | HTR2A (1.00) | HTR2AGPR84HTR1AMPOSLC6A4 | |
| SCHEMBL27661274 | 0.83 | HTR2A (0.71) | HTR2AGPR84HTR1AMPOSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612099-B2 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101321749-A | Novel vinylogous acid derivatives | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| EP-1957483-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007063010-A1 | NOVEL VINYLOGOUS ACIDS DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129421-A1 | Vinylogous acid derivatives | HOFFMANN-LA ROCHE INC. | 2007-06-07 | — | — | US | disclosed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | disclosed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | disclosed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-6583135-B2 | Treating central nervous system disorders wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity). | PHARMACIA & UPJOHN COMPANY | 2003-06-24 | — | — | US | disclosed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | disclosed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| EP-0971926-A1 | DIHYDROPYRAZINO 1,2-$i(A)-]INDOLE-1-ONE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042710-A1 | DIHYDROPYRAZINO [1,2-A-]INDOLE-1-ONE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-SYNTHELABO (FR) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | HTR2A 11/4885GPR84 328/4885HTR1A 2/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | HTR2A 9/4885GPR84 267/4885HTR1A 2/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | HTR2A 11/4885GPR84 328/4885HTR1A 2/4885 |
| US-20070129421-A1 | Vinylogous acid derivatives | CMA1, TPSG1, TPSAB1 | HTR2A 2869/4885GPR84 476/4885HTR1A 1692/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | HTR2A 9/4885GPR84 267/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.